Lect 2 Regs of Medications Flashcards

1
Q

Pure food and drug act of 1906

A
  • brought on by Upton Sinclair’s “The Jungle”
  • Prohibited the adulteration and misbranding of food/meds
  • Amended in 1912, prohibit false efficacy claims
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Sulfanilamide Elixir

A
  • circa 1937, Massengil reported a demand for liquid form of drug
  • diethylene glycol solvent was used
  • 107 deaths (renal failure and seizures)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Food, Drug, and Cosmetic act of 1938

A
  • no new drug could be marketed until proven safe for use and approved by FDA
  • labels must contain adequate directions and warnings
  • pre1938 drugs exempt
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Roles of FDA

A
  • Rulemaking
  • Issue guidance documents
  • Incorporate advice from standing advisory committees of outside experts
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Durham-Humphrey Amendment of 1951

A
  • Established 2 classes of drugs (OTC and RX)
  • RX: those that required medical supervision and a warning “caution, federal law prohibits dispensing w/o rx”
  • OTC:do not require medical supervision (still need labeling)
  • Authorized oral scripts/refills
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Thalidomide Tragedy of 1961

A
  • sleep aid and antiemetic for morning sickness
  • Dr. Frances Kelsey had concerns
  • 10,000 flipper babies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Thalidomide Today

A
  • in 2006, approved for multiple myeloma (w/dexamethasone)
  • only dispensed under STEPS
  • available only to approved professionals
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

REMS programs

A
-Risk evaluation and mitigation tool
CAN include:
-distribution of a medication guide
-Registries
-Provider training
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Kefauver-Harris Amendment of 1962

A
  • AKA drug efficacy amendment
  • required drugs to be proven safe and effective to be approved
  • transferred rx drugs advertising from FTC to FDA
  • established GMPs
  • required informed consent and ADR reporting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Orphan drug act of 1983

A

-provided tax and license incentives for manufacturers who developed drugs for rare diseases/conditions (<200K)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Wax Hatchman Amendment

A
  • AKA drug price competition and patent term restoration act of 1984
  • streamlined the generic drug approval process while giving patent extensions for innovative drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Prescription drug marketing act of 1987

A
  • in repsonse to diversionay distribution systems
  • required restrictions and recordkeeping for samples
  • prevented medical centers from reselling stock
  • required licensing of drug wholesalers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Patient protection and ACA of 2010

A
  • mandate all individuals have health insurance
  • set up exchanges for companies to compete
  • phase out donut hole
  • stop brand/generic collusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is a drug?

A
  • article in the USP/NF
  • article intended to diagnose, cure, mitigate, treat, or prevent disease
  • article intended to affect structure or function of the body
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Special food categories

A
Legal categories
-special dietary foods
-medical foods
Publicly conceived categories
-Nutraceuticals
-functional foods
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Class I recall

A

Reasonable probability product will cause serious health consequences or death (heparin 2008)

17
Q

Class II recall

A

Product may cause temporary or reversible adverse effects (Ketorolac 2010)

18
Q

Class III recall

A

Product unlikely to cause adverse health consequences

19
Q

Adulteration

A

1) consists of any filthy, putrid, or decomposed substances
2) represented as the drug not recognized in USP. wrong strength, or quality/purity below USP standards
3) mixed or packed therwith so as to reduce quality/strength

20
Q

Federal Anti-tampering act

A

Act requires certain OTC drugs, cosmetics, and devices be manufactured in tmaper resistant packaging

21
Q

Misbranding

A
  • label can’t be false/misleading
  • label must include active ingredients (in alpha)
  • adequate directions for/warnings against use
  • cannot imitate another drug
22
Q

Adulteration vs Misbranding

A

A:deals with drug’s strength, purity, and quality
M: focuses on representations made by the manufacturer on the label

23
Q

Pregnancy A

A

Adequate studies have not demonstrated a risk to fetus

24
Q

Pregnancy B

A

Animal studies failed to demonstrate risk to fetus

25
Pregnancy C
Either animal have shown an adverse effect or there are no animal/human studies
26
Pregnancy D
Positive evidence of fetal risk exists based on investigational or marketing reports
27
Pregnancy X
Studies (animal or human) demonstrate risk clearly outweighs benefit
28
Investigation of New Drug Application (INDA)
- composed of preclinical data which reflects both use and safety in animal trials - FDA has 30 days to decide if suitable for testing - After approval, may initate human trials
29
3 phases to human trials
- 1 and 2 conducted by manufacturer | - 3 conducted independently at remote clinical site with manufacturer sponsorship
30
Prescription Drug User Fee Act
- submission fees allowed FDA to hire hundreds of extra reviewers - discouraged submission of low probability NDAs - P and S ratings
31
Priority rating (in NDA)
- no other effective drugs available - more effective or safer than current available drugs - important advantage (convenient, less AE, etc)
32
Supplemental NDA
- manufacturers must use these to make changes (even minor) to drug or labeling - lower priorities may take years
33
Abbreviated NDA
- for generic drugs - proof of safety/efficacy not required - rather proof of bioequivalence and acceptable manufacturing methods are required - created by Wax-Hatchman
34
Controversial Innovator drug manufacturer practices
- producing "authorized generics" - 30 month stay from ANDA approval awarded when a patent holder sues for patent infringement - filing of 2ndary patents often for produt changes and attempts to shift market share to new product - Exclusion payments
35
Phase 1 testing
- small group of healthy people | - to evaluate the drug's toxicological, PK/PD, and safety in humans
36
Phase 2 testing
- larger group (100+) with the disease | - determine efficacy, dose, range, safety, and adverse effects
37
Phase 3 testing
- larger group (1000+) | - determine effectiveness compared to placebo
38
Phase 4 testing
- postmarketing surveillance | - required to submit ADRs ro FDA